Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer

Immune checkpoint inhibitors (ICIs) target the negative regulatory pathway of T cells and effectively reactive the anti-tumor immune function of T cells by blocking the key pathway of the immune escape mechanism of the tumor—PD-1/PD-L1, and fundamentally changing the prospect of immunotherapy for no...

Full description

Bibliographic Details
Main Authors: Yanping Li, Tianhong Chen, Tian Yi Nie, Juyuan Han, Yunyan He, Xingxing Tang, Li Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
non-small cell lung cancer
PD-1/PD-L1
response pattern
hyperprogressive disease
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1200875/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1200875/full

Similar Items